This Executive Briefing examines the growth of recruiting oncology sites globally using data from Phesi's Trial Accelerator™ platform.  

11,755 Phase I, II and III oncology clinical trial sites, open for recruitment since 2019, were analyzed to determine what impact the growth of investment in oncology trials is having on investigator sites globally.

Key findings: 

• Recruiting oncology clinical trial investigator sites have increased by 49% in the past five years with China a significant driving force
• A lack of precision in site selection and  reliance on over-burdened sites is impacting the  speed and cost of clinical development 
• The use of data  for more effective decision-making in design and operations holds the key to smarter trials and faster cures